Verastem (VSTM) Expected to Announce Earnings on Thursday

Key Points

• Verastem is expected to announce its Q2 2025 earnings on August 7th, forecasting a loss of ($0.64) per share and revenue of $6.01 million.
• Recent stock performance shows Verastem trading at $6.23 with a market capitalization of $342.34 million, but it has struggled with earnings, reporting a loss of ($0.96) per share for the last quarter.
• Analyst ratings for Verastem are mixed, with one "sell," eight "buy" ratings, and an average target price of $13.38, following various adjustments from different financial institutions.

Verastem (NASDAQ:VSTM - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $6.01 million for the quarter.

Verastem (NASDAQ:VSTM - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.24). On average, analysts expect Verastem to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verastem Price Performance

Shares of NASDAQ:VSTM traded down $0.13 on Monday, hitting $5.96. The company's stock had a trading volume of 546,760 shares, compared to its average volume of 1,673,824. Verastem has a 1 year low of $2.10 and a 1 year high of $9.10. The company has a 50-day simple moving average of $5.56 and a 200 day simple moving average of $6.03. The company has a market capitalization of $327.23 million, a PE ratio of -1.87 and a beta of 0.83.

Insider Buying and Selling at Verastem

In other Verastem news, CFO Daniel Calkins sold 11,143 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.13, for a total value of $90,592.59. Following the completion of the sale, the chief financial officer directly owned 114,055 shares of the company's stock, valued at approximately $927,267.15. This represents a 8.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dan Paterson sold 17,808 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $5.13, for a total transaction of $91,355.04. Following the completion of the sale, the chief executive officer owned 443,839 shares of the company's stock, valued at approximately $2,276,894.07. This trade represents a 3.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,976 shares of company stock valued at $687,047 in the last three months. Company insiders own 2.10% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Verastem stock. AQR Capital Management LLC raised its holdings in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 78.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,603 shares of the biopharmaceutical company's stock after buying an additional 27,477 shares during the period. AQR Capital Management LLC owned 0.12% of Verastem worth $377,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 88.37% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on VSTM shares. Mizuho lowered their price objective on shares of Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Jefferies Financial Group assumed coverage on Verastem in a research report on Thursday, April 10th. They set a "buy" rating and a $15.00 target price on the stock. HC Wainwright raised their price objective on Verastem from $10.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Wall Street Zen cut Verastem from a "hold" rating to a "sell" rating in a report on Friday, April 18th. Finally, Royal Bank Of Canada upgraded shares of Verastem from an "outperform" rating to a "moderate buy" rating and dropped their target price for the company from $16.00 to $12.00 in a report on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $13.38.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.